Subcutaneous Biologics Market

Subcutaneous Biologics Market Overview

The global subcutaneous biologics market, valued at USD 250.6 billion in 2025, is projected to reach USD 267.6 billion in 2026 and USD 233.0 billion by 2035, during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

The new research study consists of industry trends, detailed analysis of approved and clinical subcutaneous biologics, detailed subcutaneous formulation technology landscape, partnerships and collaborations, opportunity analysis for approved drugs, and subcutaneous biologics market forecast for formulation technologies.

The subcutaneous biologics market growth over the next decade is likely to be the result of increased adoption of self-administration devices along with various technological advancements in subcutaneous delivery of biologic drugs. Over the last few years, the pharmaceutical industry has witnessed a rise in the number of biologic drugs, including gene therapies, blood products, cell products, antibodies and protein therapeutics. Unlike the traditional chemical-based medications (which are easy to develop and are relatively cheaper), these drugs exhibit some challenges during the drug development process. These include high molecular weight, complex chemical structures, susceptibility to degradation post-administration and complex manufacturing processes.

Lately, with the advent of technological advancements, to circumvent these challenges, the pharmaceutical companies are actively engaged in the development of these biologic drugs to treat a plethora of diseases. The technological advancements involve the formulation of subcutaneous biologics (including conjugation, amino acid and encapsulation) as well as novel drug delivery systems (including autoinjectors, pre-filled syringes and needle free drug delivery) to deliver these highly-viscous formulations. The industry has witnessed an increase in the number of the United States Food and Drug Administration (USFDA) approved biologic drugs in the last few years. Notably, in the first quarter of 2024, nine biologics received the USFDA approval. This paradigm shift observed towards the preference of biologics can be attributed to their ability to offer targeted treatment (with minimal drug interactions) due to their specific binding and metabolic pathways.

Traditionally, biologics were designed for delivery via intravenous routes due to rapid systemic circulation and potent bioavailability of these large molecules. Although intravenous administration is an effective method for delivering the biologics, it frequently necessitates the need for regular administration by healthcare professionals, which can pose a challenge in terms of medication adherence. Meanwhile, the strategies and devices for the subcutaneous administration of biologics are gaining traction from the healthcare providers, owing to the effectiveness, tolerability and safety. Further, the shift towards subcutaneous biologics is driven by the growing demand for self-administrable therapies and availability of user-friendly drug delivery devices, such as autoinjectors and prefilled syringes.

Subcutaneous Biologics Market Segmentation Insights

The market report presents an in-depth analysis of the various subcutaneous biologics companies that are engaged in the market, across different segments, as defined in the table below:

Subcutaneous Biologics Market: Report Attributes / Market Segmentations

Key Report Attributes	Details
Historical Trend	Since 2018
Forecast Period	Till 2035
Market Size 2035 (Approved Subcutaneous Biologics)	$ 233.0 Billion
Market Size 2035 (Formulation Technologies Market)	$ 2,724 Million
Type of Biologic	Antibodies Nucleotides Proteins
Type of Therapy	Monotherapies Combination Therapies Both (Monotherapies and Combination Therapies)
Method of Administration	Injection Infusion Both (Injection and Infusion)
Fundamental Principle	Encapsulation Complex Formation Conjugation Amino acid Interaction Other Fundamental Principles
End User	Pharmaceutical and Biopharmaceutical Companies Biotechnology Companies MedTech Companies Contract Development and Manufacturing Organizations Educational Institutes Medical Equipment Manufacturers Other End Users
Payment Method Employed	Milestone Payments Upfront Payments
Therapeutic Area	Autoimmune Disorders Bone Disorders Hematological Disorders Infectious Diseases Inflammatory Disorders Metabolic Disorders Neurological Disorders Ocular Disorders Oncological Disorders Other Disorders
Type of Drug Delivery Device	Large Volume Wearable Injectors Autoinjectors Needle-free Injection System Novel Drug Reconstitution System Prefilled Syringes
Geographical Regions	North America  Europe  Asia-Pacific  Middle East and North Africa Latin America
Key Players Profiled	Adocia Alteogen Ascendis Pharma CD Bioparticles Creative Biolabs Creative BioMart Foresee Pharmaceuticals Pacira Biosciences The Wyss Institute  Xeris Biopharma (Full list of 40+ technology developers captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Market Landscape for Approved Subcutaneous Biologics Approved Subcutaneous Biologics Success Protocol Analysis Market Landscape for Clinical Subcutaneous Biologics Subcutaneous Formulation Technology Landscape Technology Competitiveness Analysis Partnerships and Collaborations (Subcutaneous Formulation Technology) Approved Subcutaneous Biologics Market Forecast and Opportunity Analysis Subcutaneous Biologics Market Forecast and Opportunity Analysis for Formulation Technologies

One of the key objectives of the market report was to estimate the current subcutaneous biologics market size, opportunity and the market growth potential (for approved subcutaneous biologics and subcutaneous formulation technology developers), over the forecast period. Based on multiple parameters and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035.

The market report also features the likely distribution of the current and forecasted opportunity within the subcutaneous biologics market across various segments, such as type of biologic (antibodies, nucleotides and proteins), type of therapy (monotherapies, combination therapies and both (monotherapies and combination therapies)), method of administration (injection, infusion and both (injection and infusion)), fundamental Principle (encapsulation, complex formation, conjugation, amino acid interaction and other fundamental principles), end user (pharmaceutical and biopharmaceutical companies, biotechnology companies, MedTech companies, contract development and manufacturing organizations, educational institutes, medical equipment manufacturers and other end users), payment method employed (milestone payments and upfront payments), therapeutic area (autoimmune disorders, bone diseases, hematological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, ocular disorders, oncological disorders and other disorders), drug delivery device (autoinjectors, cartridges, infusion pumps, pen-injectors, pre-filled syringes, vials and other drug delivery devices), geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America), leading players and sales forecast.

In order to account for future uncertainties and to add robustness to our model, we have provided three subcutaneous biologics market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s evolution.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

• Founder and Chief Executive Officer, Small Company, US
• Founder and Chief Technology Officer, Mid-sized Company, UK
• Chief Executive Officer & Founder, Small Company, US
• Chief Executive Officer, Small Company, Denmark
• Chief Executive Officer, Mid-sized Company, US
• Chief Technical Officer, Very Large Company, India
• Vice President and Chief Scientist, Large Company, Israel
• Senior Portfolio Director, Large Company, US
• Managing Director, Small Company, Austria
• Communication Leader, Mid-sized Company, France
• Former Founder and Chief Scientific Officer, Vice President and Product Development, Former Senior Scientist Formulation, Mid-sized Company, US
• Former Chief Commercial Officer, Large Company, Germany
• Anonymous, a US-based company
• Anonymous, a Europe-based company

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Subcutaneous Biologics Market Share Insights

Approved Subcutaneous Biologics Market

Market Share by Type of Biologic

Based on type of biologic, the global market for approved subcutaneous biologics is segmented into antibodies, nucleotides and proteins. It is worth mentioning that, currently, antibodies occupy the highest share in the market attributing to its higher target specificity, increased safety profile and lower toxicity. Further, approved subcutaneous biologics market for nucleotides is expected to witness substantial growth during the forecast period.

Market Share by Type of Therapy

The global market for approved subcutaneous biologics is segmented across monotherapy, combination therapy, and both monotherapy and combination therapies. Both monotherapy and combination therapies segments occupy the largest current market share and is expected to witness a substantial growth during the forecast period.

Market Share by Method of Administration

This segment highlights the distribution of global market for approved subcutaneous biologics across different types of methods of administration, such as injection, infusion, and both injection and infusion. It is worth highlighting that, presently, majority of the approved subcutaneous biologics market share is occupied by injection as a method of administration and is expected to remain dominant, during the forecast period. This can be attributed to the fact that delivery via injections is more convenient for the patients as well as healthcare professionals. Additionally, the chances of any allergic reaction and fluid overload, are also reduced.

Market Share by Therapeutic Area

Based on therapeutic area, the global market for approved subcutaneous biologics is segmented into autoimmune disorders, metabolic disorders, oncological disorders, hematological disorders, inflammatory disorders, neurological disorders, bone disorders and other disorders. Currently, autoimmune disorders segment occupies the highest subcutaneous biologics market share. This can be primarily attributed to the high efficacy of these drugs in the treatment of various prevalent autoimmune disorders, such as psoriasis, ankylosing spondylitis, ulcerative colitis and Crohn's disease. However, during the forecast period, metabolic disorders segment is likely to capture a larger market share owing to the rising preference of subcutaneous injection for the administration in patients suffering from diabetes mellitus and obesity (wherein long-term administration of drugs is required).

Market Share by Geographical Regions

This segment highlights the distribution of approved subcutaneous biologics market across various geographies, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projections, presently, North America is likely to capture a majority share (~50%) in the overall market. Further, it is worth highlighting that the market in Asia-Pacific is expected to grow at a relatively higher CAGR, during the forecast period, till 2035. The growth of the market in Asia-Pacific can be ascribed to the rapidly growing patient population, the rising incidence of chronic disorders (including neurological disorders, genetic disorders and autoimmune disorders), and the rising demand for effective and advanced therapeutics. Further, the increasing investments and initiatives taken by regulatory bodies in the Asian countries to promote the adoption of biologics among patients and physicians is likely to drive the market in future.

Subcutaneous Biologics Market for Formulation Technologies

Market Share by Fundamental Principle

The global subcutaneous biologics formulation technology market is segmented across various fundamental principles, such as amino acid interaction, complex formation, conjugation, amino acid interaction, encapsulation and other fundamental principles. Presently, the revenues generated through the licensing of technologies that are based on encapsulation principle are likely to capture majority share in the overall market and is expected to remain dominant during the forecast period. It is worth highlighting that encapsulation helps in increasing the solubility of the biologics that are hydrophobic, which further results in increased absorption of the drugs in the patient’s body. Further, drug encapsulation also leads to high target specificity, thereby reducing the likelihood of adverse effects (that usually occur due to high systemic exposure).

Market Share by End User

The global subcutaneous biologics formulation technology market caters to a wide variety of end users, including biotechnology companies, contract development and manufacturing organizations, educational institutes, medical equipment manufacturers, MedTech companies, pharmaceutical and biopharmaceutical companies and other end users. Notably, pharmaceutical and biopharmaceutical companies are expected to currently capture the highest share in the market, However, biotechnology companies are estimated to grow at a relatively higher CAGR, during the forecast period.

Market Share by Therapeutic Area

This segment highlights the distribution of global subcutaneous biologics formulation technology market across different therapeutic areas, such as autoimmune disorders, bone diseases, hematological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, ocular disorders, oncological disorders and other disorders. It is worth highlighting that the oncological disorders hold the largest share in the current technology market. This can be attributed to the high incidence rate of oncological disorders, accounting for around 1.9 million cases in 2022 and over 2 million cases in 2023. Further, the global subcutaneous biologics market for formulation technology for autoimmune disorders is estimated to grow at the highest CAGR, during the forecast period.

Market Share by Key Geographical Regions

This segment highlights the distribution of subcutaneous biologics formulation technology market across various geographies, such as North America, Europe and Asia-Pacific. It is worth highlighting that North America captures close to 65% of the current global subcutaneous biologics market for formulation technology. Further, the subcutaneous biologics formulation technology market in Asia-Pacific is expected to grow with the highest CAGR, during the forecast period. The growth of market in Asia-Pacific can be attributed to the rise in number of technology developers in this region, that will be actively involved in inking licensing deals with the drug developers.

Market Share by Payment Method Employed

Based on payment method employed, the global subcutaneous formulation technology market is segmented into milestone payments and upfront payments. It is worth mentioning that milestone payments occupy the majority share in the current market and this trend is unlikely to change in the future.

Subcutaneous Biologics Market: Key Insights

The “Subcutaneous Biologics Market (5th Edition): Industry Trends and Global Forecasts, till 2035” report features an extensive study of the approved subcutaneous biologics, clinical subcutaneous biologics, detailed subcutaneous formulation technology landscape, partnerships and collaborations, market forecast and opportunity analysis, during the given forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the market report are briefly discussed below.

Advantages of Subcutaneous Administration over Other Parenteral Routes

The administration of biologics (and small molecules) via the subcutaneous route has emerged as a transformative approach to treat patients suffering from various diseases (specifically chronic diseases). This can be attributed to the fact that subcutaneous administration of drugs is relatively simple and can be self-administered by patients, making them suitable for home use. This reduces the need for healthcare professionals, which is often required for other routes of administration (including intramuscular and intravenous). Further, subcutaneous administration allows the efficient delivery of drugs directly into the fatty tissue just beneath the skin and provides a slower, more sustained release of drugs, which can lead to improved efficacy and reduced side effects.

Competitive Landscape of Approved Subcutaneous Biologics Market

During our research, we came across more than 150 unique subcutaneous biologics that are currently approved for the treatment of various therapeutic areas. Notably, more than 35 subcutaneous biologics have been approved post-2022. In July 2024, Novo Nordisk received the approval for their once-weekly basal insulin Awiqli® (insulin icodec) by the European Medicines Agency (EMA) for the treatment of diabetes in adults.  It is worth noting that the Awiqli is available as connected pen-injector, which enables personalized and automated dose guidance to patients. Further, around 50% of the subcutaneous biologics approved are proteins; of which 30% are being used for the management of metabolic disorders, such as diabetes mellitus and obesity.

Competitive Landscape of Clinical-stage Subcutaneous Biologic Developers

The current subcutaneous biologics market landscape features the presence of nearly 120 drug developers that have clinical-stage subcutaneous biologics in their pipeline. The landscape is well-fragmented, featuring the presence of small, mid-sized, large and very large companies having the required expertise to develop and commercialize these therapies. Further, more than 50% of the drug developers are headquartered in North America; notable examples (in alphabetical order) include Apellis Pharmaceuticals, Eli Lilly, Pfizer and TuHURA Biosciences.

Need for Subcutaneous Formulation Technology

Despite the various advantages associated with subcutaneous route of administration, there are certain challenges in regard to the delivery of drugs through this route. Notably, the subcutaneous injections are typically limited to small volumes, generally between 1 to 2 mL, (although some formulations can accommodate up to 3 mL), which may pose a challenge for the delivery of large volume of drugs. Further, through subcutaneous administration, the absorption of drugs depends on several factors, such as the injection site, temperature, and individual patient characteristics, which leads to inconsistent therapeutic effects. To address these challenges, various developers are focusing on the development of technology platforms to enhance the efficacy of biologics via subcutaneous route.

Competitive Landscape of Subcutaneous Formulation Technology Market

The current technology landscape features the presence of over 40 companies engaged in the development of subcutaneous formulation technologies. It is worth mentioning that around 20% of the technologies operate via encapsulation technology for the delivery of biologics and small molecules. Further, a number of these technologies are also used for the preparation of formulations that are intended for delivery via the intramuscular and intravenous routes.

Strategic Partnerships Driving Technological Advancements in Subcutaneous Biologics Market

Stakeholders involved in development of subcutaneous biologics have forged several partnerships with other stakeholders to drive technological advancements for the development of subcutaneous biologics, in order to support the safe, effective formulation and delivery of highly-viscous biologics. These include technology licensing agreements, technology evaluation agreements, research and development agreements and product development and commercialization agreements. It is worth highlighting that multiple agreements were forged in the past three years. Recently, in May 2024, Serina Therapeutics entered into an agreement with Enable Injections for the development and commercialization of SER-252 (POZ-apomorphine) using the latter company’s enFuse wearable drug delivery platform for the treatment of Parkinson's disease.

Drug Delivery Platforms for the Small Molecules and Biologics Subcutaneous Delivery

Subcutaneous drug delivery systems have evolved significantly in recent years, offering a range of advantages over traditional administration routes. Various drug delivery platforms, such as large volume injectors, autoinjectors, pen-injectors, needle-free injection systems, drug reconstitution systems and prefilled syringes aim to enhance patient convenience and medication adherence. Within the wearable injectors domain, the on-body injectors offer sustained therapeutic effects, thereby enhancing patient adherence and treatment effectiveness. In addition, large volume wearable injectors have been proven to improve medication adherence by simplifying the administration process. Further, autoinjectors are spring-loaded syringes working on various mechanisms (ranging from simple push-on-skin devices to fully automated button activated technologies) and include pre-measured medication, which eliminates the need to draw medication from a separate vial, thus resolving various injection-related compliance issues faced by the patients.

Prefilled syringes are another type of primary packaging system that are pre-loaded with a precise dose of parenteral medication (in a ready to inject format), eliminating the need for manual filling. Presently, different types of prefilled syringes are available in the market, including dual chamber prefilled syringes (such syringes store liquid and lyophilized components in different chambers), flush syringes (syringes containing sterile solution that is used to clear intravenous catheters, cannulas or other vascular access devices), and safety syringe and safety needles (syringes equipped with mechanisms that prevent needlestick injuries and ensure safety of the healthcare worker).

Over the years, there has been an increased trend towards smart drug delivery devices, including connected autoinjectors and smart pen injectors. These devices allow for the tracking of medication administration, dose reminders, and data sharing with healthcare providers, ultimately improving patient adherence and management of chronic conditions.

Key Companies Engaged in Subcutaneous Biologics Market

Examples of key players engaged in development of subcutaneous biologics or formulation technologies (have been profiled in full report, arranged in alphabetical order) include Adocia, Alteogen, Ascendis Pharma, CD Bioparticles, Creative Biolabs, Creative BioMart, Foresee Pharmaceuticals, Pacira Biosciences, Wyss Institute and Xeris Biopharma.

This market report includes an easily searchable excel database including all the players that are engaged in either developing subcutaneous biologics or providing formulation technology.

Subcutaneous Biologics Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this industry, across different segments. Amongst other elements, the market report includes:

• A preface providing an introduction to the full report, Subcutaneous Biologics Market (5th Edition), till 2035.

• An outline of the systematic research methodology adopted to conduct this study, covering research assumptions, project and forecast methodologies, primary and secondary research approaches, along with the various analytical frameworks utilized / considered in the report.
• An overview of various comprehensive methodologies and frameworks used to forecast and analyze subcutaneous biologics market trends. Further, it discusses the key factors influencing market dynamics and emphasizes the robust quality control framework adopted to ensure transparency and credibility in the insights presented throughout the report.
• A brief context of the economic factors that impact the overall market for subcutaneous biologics, including currency fluctuations, foreign exchange rates, and known trade barriers. In addition, it evaluates the effects of global recession and inflation on the growth of the market, drawing insights from key historical events to inform decision making in the future.
• An executive summary of the insights captured in our research, featuring key takeaways from the current state of subcutaneous biologics market and its likely evolution in the mid-long term.
• A general introduction on different types of therapeutic molecules (biologics and small molecules) comparing their characteristics, such as molecular size, molecular weight, molecular structure, immunogenicity, stability and manufacturing. The chapter also highlights different types of biologically derived products that are currently being developed by several players in the industry. Additionally, it includes information on the various challenges associated with the parenteral route of drug delivery, specifically those related to the traditional intravenous (infusion) route. Further, this chapter discusses about subcutaneous formulations, which includes different approaches of delivery of such biologics, method of administration, advantages and limitations associated with this route, along with the relevant regulatory guidelines.
• A comprehensive assessment of the overall market landscape of approved subcutaneous biologics, based on several relevant parameters, such as initial approval year (pre-1991, 1991-2000, 2001-2010, 2011-2020 and post-2020), type of biologic (antibodies, nucleotides, proteins, vaccines and others), type of therapy (monotherapy and combination therapy), route of administration (subcutaneous and intravenous / intramuscular), method of administration (injection and infusion), dosing frequency, concentration of dose, target disease indication (anemia, ankylosing spondylitis, Crohn’s disease, diabetes mellitus, growth hormone deficiency, neutropenia, plaque psoriasis, primary immunodeficiency, psoriatic arthritis, rheumatoid arthritis and turner syndrome), therapeutic area (autoimmune disorders, bone disorders, dermatological disorders, genetic disorders, hematological disorders, hormonal disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders, women’s health and other disorders) and type of drug delivery device (autoinjectors, cartridges, infusion pumps, pen-injectors, prefilled syringes, vials and other drug delivery devices). Further, the chapter includes an overview on the landscape of developers engaged in this domain, presenting a detailed analysis based on parameters such as year of establishment, company size (based on employee count) and location of headquarters and most active developers (in terms of number of approved drugs).
• An insightful success protocol analysis of the leading subcutaneous biologics (in terms of value creation), taking into consideration several relevant parameters, such as drug efficacy / success rate, target disease indication burden, global competition (with respect to industry players), therapy price, geographical reach and disease prevalence.
• A comprehensive assessment of the overall market landscape of clinical-stage subcutaneous biologics, based on several relevant parameters, such as status of development (late-stage (pre-registration, phase III) and early-stage (phase II and phase I)), type of biologic (antibodies, nucleotides, proteins, vaccines and others), type of therapy (monotherapy and combination therapy), mechanism of action (inhibition, modulation, stimulation and other mechanisms), dosing frequency, target disease indication (Alzheimer's disease, asthma, atopic dermatitis, diabetes mellitus, multiple myeloma, nonalcoholic steatohepatitis, obesity, systemic lupus erythematosus, ulcerative colitis and other indications), therapeutic area (allergic disorders, autoimmune disorders, bone disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, hepatic disorders, hormonal disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, nephrological disorders, neurological disorders, oncological disorders, ophthalmological disorders, respiratory disorders, women's health and other disorders) and drug designation (breakthrough therapy, fast track designation, orphan drug designation, PRIME designation and rare pediatric disease). Further, the chapter includes an overview on the landscape of developers engaged in this domain, presenting a detailed analysis based on parameters such as year of establishment, company size (based on employee count), location of headquarters and most active developers (in terms of number of subcutaneous biologics in clinical-stage of development).
• A detailed overview of the current market landscape of subcutaneous formulation technologies, along with information on several relevant parameters, such as fundamental principle (encapsulation, complex formation, conjugation, amino acid interaction, dehydration and others), type of molecule (biologics and small molecules), route of administration (subcutaneous, intramuscular, intravenous, oral, local, pulmonary, intraocular, intratumoral, topical, epidural, intathecal, intraarticular and others), therapeutic area (oncological disorders, metabolic disorders, neurological disorders, infectious diseases, cardiological disorders, hematological disorders, autoimmune disorders, endocrine disorders, hormonal disorders, immuno-deficiency disorders, inflammatory disorders, ocular disorders, ophthalmological disorders and other disorders) and key characteristics (extended / controlled / sustained drug release, thermostability / stability during storage, low volume formulations, high concentration, low viscosity, reformulation, high drug volume and other characteristics). In addition, this chapter provides a detailed analysis of subcutaneous formulation technology developers based on their year of establishment, company size (in terms of employee count) and location of headquarters.
• An insightful technology competitiveness analysis of the subcutaneous formulation technologies, based on several relevant parameters, such as the company strength (in terms of years of experience) and technology strength (in terms of fundamental principle, type of molecule, route of administration, therapeutic area and key characteristics).
• Elaborate profiles of prominent subcutaneous formulation technology developers based in North America, Europe and Asia-Pacific. Each company profile features a brief overview of the company, along with information on location of headquarters, year of establishment, number of employees, leadership team, contact details, financial information (if available), technology portfolio, recent developments and an informed future outlook.
• A detailed analysis of the partnerships inked between stakeholders in subcutaneous formulation technology domain, since 2020, covering technology licensing agreements, technology evaluation agreements, product development agreements, acquisitions and other relevant agreements.
• An elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, novel drug reconstitution systems, prefilled syringes and implants.

• An insightful product competitiveness analysis of the subcutaneous delivery system, such as large volume wearable injectors, autoinjectors, needle-free injectors and prefilled syringes, taking into consideration the supplier power and product specific information.
• A detailed discussion on industry affiliated trends, opportunities and challenges, under a SWOT analysis, which are likely to impact the evolution of subcutaneous biologics market; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
• A detailed market forecast of approved subcutaneous biologics in order to estimate the current market size and future opportunity over the next 11 years. Based on multiple parameters such as, historical sales of the drugs, peak sales and through secondary research, we have provided an informed estimate on the market size, till 2035. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed projections of the current size and future opportunity for approved subcutaneous biologics across different types of biologics, namely antibodies, proteins and nucleotides.
• Detailed projections of the current size and future opportunity for approved subcutaneous biologics across different types of therapy, namely monotherapy, combination therapy, and both monotherapy and combination therapy.
• Detailed projections of the current size and future opportunity within the approved subcutaneous biologics market across different methods of administration, namely injection, infusion, and both injection and infusion.
• Detailed projections of the current size and future opportunity within the market for approved subcutaneous biologics across different therapeutic areas, namely autoimmune disorders, metabolic disorders, oncological disorders, hematological disorders, inflammatory disorders, neurological disorders, bone disorders and other disorders.
• Detailed projections of the current size and future opportunity within the approved subcutaneous biologics market across different geographical regions, namely North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America.
• Detailed projections of the current and future revenues from the sales of approved subcutaneous biologics (for which sales data was available).
• A detailed projection of the leading players in the developing subcutaneous biologics based on relevant parameters.
• A detailed market forecast analysis in order to estimate the existing market size and future opportunity for the subcutaneous formulation technologies market, till the year 2035. Based on multiple parameters, such as revenues generated from technology licensing deals and thorough secondary research, we have provided an informed estimate on the market evolution over the next 11 years. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed projections of the current size and future opportunity within the subcutaneous formulation technologies market across different fundamental principles, namely encapsulation, complex formation, conjugation, amino acid interaction and other fundamental principles.
• Detailed projections of the current size and future opportunity within the subcutaneous formulation technologies market across different types of end users, namely pharmaceutical and biopharmaceutical companies, biotechnology companies, MedTech Companies, contract development and manufacturing organizations, educational institutes, medical equipment manufacturers and other end users.
• Detailed projections of the current size and future opportunity within the subcutaneous formulation technologies market across different therapeutic areas, namely oncological disorders, metabolic disorders, ocular disorders, infectious disorders, autoimmune disorders, neurological disorders, immunological disorders and other disorders.
• Detailed projections of the current size and future opportunity within the subcutaneous formulation technologies market across different key geographical regions, namely North America, Europe and Asia-Pacific.
• Detailed projections of the current size and future opportunity within the subcutaneous formulation technologies market across different payment methods employed, namely milestone payments and upfront payments.
• A detailed projection of the leading players in the subcutaneous biologics formulation technology market based on relevant parameters.
• An overview of market forecast analysis analysis in order to estimate the existing market size and future opportunity across large volume wearable injectors, autoinjectors, needle-free injection system, novel drug reconstitution system and prefilled syringes.

Recent Developments in Subcutaneous Biologics Market

Several recent developments have taken place in the market, some of which have been outlined below.

• In April 2026, Eisai’s Biologics License Application for the subcutaneous formulation of lecanemab was accepted for review in China, advancing a potential subcutaneous version of the Alzheimer’s biologic that could expand the subcutaneous biologics market in the CNS therapeutic area.
• In January 2026, FDA approved the use of Darzalex Faspro  in combination with VRd for newly diagnosed multiple myeloma patients, expanding the role of subcutaneous antibody therapies in frontline hematologic malignancy regimens and driving uptake of SC formulated biologics.
• In December 2025, FDA approved Merck & Co.’s subcutaneous pembrolizumab formulation, reducing administration for solid tumor indications from about 30 minutes for IV infusion to one to two minutes via subcutaneous injection.
• In November 2025, The European Medicines Agency validated and subsequently approved a subcutaneous formulation of pembrolizumab  for multiple adult solid tumor indications, aligning with the FDA’s prior nod and reinforcing regulatory consensus on SC checkpoint inhibitor conversions. 

Author(s): Dakshita Dhawan, Manika Goyal, Rupanshi Sharma, Prachi Bhalla

Frequently Asked Questions

Question 1: Why are biologics given subcutaneously?

Answer: Subcutaneous route offers numerous advantages for administration of biologics, including better efficacy, safety, convenience and less painful for the patients. Moreover, these drugs aids in increasing medication adherence and reduced visits to the hospitals as subcutaneous biologics can be self-administered.

Question 2: How big is the subcutaneous biologics market?

Answer: The current global subcutaneous biologics market size for approved drugs is estimated to be $267.6 billion.

Question 3: What is the estimated subcutaneous biologics market growth?

Answer: The market for approved subcutaneous biologics is estimated to grow over the next 2-3 years; however, due to the impending patent expiry of a number of products, the global market is expected to decline by 2035. Overall, the market will likely decline at an annualized rate of 0.1% during the forecast period, till 2035.

Question 4: Which region is expected to hold the majority of the subcutaneous biologics market share in the year 2035?

Answer: North America is expected to hold the majority share (47%) by 2035.

Question 5: How big is the subcutaneous injection market?

Answer: The global subcutaneous injection market (for approved biologics) is estimated to reach $ 233.0 billion in 2035.

Question 6: How many drug delivery systems for the administration of subcutaneous biologics are currently available in the market?

Answer: Presently, over 5 drug delivery systems are marketed / being developed for subcutaneous delivery.

Question 7: What is the trend in the subcutaneous biologics market?

Answer: Presently, more than 150 unique drug candidates have been approved for the administration of different types of biologics and small molecules. Moreover, over 340 subcutaneous biologics are currently being developed in clinical stage of development.

Question 8: How many subcutaneous biologics technologies are currently available in the market?

Answer: Presently, more than 40 technologies are available for the formulation / delivery of molecules for the treatment of various indications.